BR112012019520A2 - macromoleculas multivalentes polianionicas para alvejamento intracelular da sintese de proteina e proliferacao - Google Patents
macromoleculas multivalentes polianionicas para alvejamento intracelular da sintese de proteina e proliferacaoInfo
- Publication number
- BR112012019520A2 BR112012019520A2 BR112012019520-4A BR112012019520A BR112012019520A2 BR 112012019520 A2 BR112012019520 A2 BR 112012019520A2 BR 112012019520 A BR112012019520 A BR 112012019520A BR 112012019520 A2 BR112012019520 A2 BR 112012019520A2
- Authority
- BR
- Brazil
- Prior art keywords
- proliferation
- polyanionic
- protein synthesis
- intracellular targeting
- targeting
- Prior art date
Links
- 229920002521 macromolecule Polymers 0.000 title abstract 4
- 230000003834 intracellular effect Effects 0.000 title abstract 3
- 230000035755 proliferation Effects 0.000 title abstract 3
- 230000008685 targeting Effects 0.000 title abstract 3
- 238000001243 protein synthesis Methods 0.000 title abstract 2
- 230000014616 translation Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003855 cell nucleus Anatomy 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004940 nucleus Anatomy 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
- C08G83/003—Dendrimers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polyethers (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
macromoléculas multivalentes polianiônicas para alvejamento intracelular da síntese de proteína e proliferação. a presente invenção refere-se a métodos e composições para alvejar moléculas intracelulares envolvidas na proliferação e síntese de proteína de células ativadas macromoléculas multivalentes polianiônicas. em um aspecto particular, grupos sulfato múltiplos ligados ao poliol são especificamente alvejados ao citoplasma e núlceo de células proliferadoras e ativadas. a invenção também compreende novos compostos e formulações macromoleculares polianiônicos.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10001104.8 | 2010-02-03 | ||
EP10001104 | 2010-02-03 | ||
EP10001655 | 2010-02-18 | ||
EP10001655.9 | 2010-02-18 | ||
EP10002121 | 2010-03-02 | ||
EP10002121.1 | 2010-03-02 | ||
PCT/EP2011/000425 WO2011095311A1 (en) | 2010-02-03 | 2011-01-31 | Polyanionic multivalent macromolecules for intracellular targeting of proliferation and protein synthesis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012019520A2 true BR112012019520A2 (pt) | 2018-03-13 |
Family
ID=43981117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012019520-4A BR112012019520A2 (pt) | 2010-02-03 | 2011-01-31 | macromoleculas multivalentes polianionicas para alvejamento intracelular da sintese de proteina e proliferacao |
Country Status (13)
Country | Link |
---|---|
US (1) | US8877171B2 (pt) |
EP (1) | EP2531221B1 (pt) |
JP (2) | JP5866301B2 (pt) |
CN (1) | CN102781478A (pt) |
AU (1) | AU2011212742B2 (pt) |
BR (1) | BR112012019520A2 (pt) |
CA (1) | CA2788736C (pt) |
DK (1) | DK2531221T3 (pt) |
ES (1) | ES2730744T3 (pt) |
HU (1) | HUE045311T2 (pt) |
NZ (1) | NZ601550A (pt) |
PL (1) | PL2531221T3 (pt) |
WO (1) | WO2011095311A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014051109A1 (ja) * | 2012-09-28 | 2014-04-03 | 協和発酵キリン株式会社 | 抗ヒトbmp9抗体および該抗体を有効成分とする異所性骨化疾患の治療剤 |
WO2014114183A1 (zh) * | 2013-01-23 | 2014-07-31 | 北京市丰硕维康技术开发有限责任公司 | 一种治疗肿瘤细胞增生性疾病的铂(ii)类化合物 |
EP2923695A1 (en) | 2014-03-25 | 2015-09-30 | DendroPharm GmbH | Hyperbranched polyglycerol sulfates with hydrophobic cores |
WO2015170573A1 (ja) * | 2014-05-08 | 2015-11-12 | 公立大学法人大阪府立大学 | リンパ節イメージング剤 |
EP3142641B1 (de) | 2014-05-13 | 2020-11-25 | DendroPharm GmbH | Formulierungen zur behandlung von hyperthyreose |
EP3145984B1 (en) * | 2014-05-21 | 2022-02-23 | ICD-Therapeutics GmbH | Therapeutic conjugates with sulfated dendrimers for intracellular targeting |
EP3048130A1 (en) * | 2015-01-20 | 2016-07-27 | Freie Universität Berlin | Anionic linear polyglycerol derivatives, a method for manufacturing and applications |
WO2016166317A1 (en) * | 2015-04-15 | 2016-10-20 | Freie Universität Berlin | Polyglycerol derivative and a method for manufacturing the same |
DE102015121366A1 (de) | 2015-12-08 | 2017-06-08 | Dendropharm Gmbh | Analgetische Zusammensetzungen mit Nanocarriern und ihre Verwendung |
EP3484527A1 (en) | 2016-07-13 | 2019-05-22 | Freie Universität Berlin | Polyglycerol derivative for use in diagnosing a disease at an early stage |
EP4134073A1 (en) | 2021-08-11 | 2023-02-15 | HM HerbaMedica GmbH | Pharmaceutical compositions comprising dendritic nanocarriers and cannabis active agents |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474765A (en) | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
AU678469B2 (en) * | 1993-05-03 | 1997-05-29 | Genentech Inc. | Inhibition of leukocyte adhesion |
CA2210500A1 (en) | 1995-01-16 | 1996-07-25 | Commonwealth Scientific And Industrial Research Organisation | Therapeutic compound - fatty acid conjugates |
ATE264694T1 (de) | 1995-01-30 | 2004-05-15 | Daiichi Pure Chemicals Co Ltd | Diagnostisches markierungsmittel |
JPH11140038A (ja) * | 1997-11-04 | 1999-05-25 | Kanebo Ltd | カルボン酸誘導体 |
JPH11246503A (ja) * | 1998-03-04 | 1999-09-14 | Sumitomo Pharmaceut Co Ltd | シクロヘキサン誘導体 |
DE10056136A1 (de) * | 2000-11-07 | 2002-05-16 | Nemod New Modalities | Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen |
CA2462261A1 (en) | 2001-10-03 | 2003-04-10 | Miravant Pharmaceuticals, Inc. | Chlorin photosensitizing agents for use in photodynamic therapy |
AU2002336636A1 (en) | 2001-10-03 | 2003-04-14 | Miravant Pharmaceuticals, Inc. | Photosensitizing carbamate derivatives |
DE102006036326A1 (de) * | 2006-08-03 | 2008-02-07 | Charité - Universitätsmedizin Berlin | Dendritische Polyglycerolsulfate und -sulfonate und deren Verwendung bei entzündlichen Erkrankungen |
EP2100621A1 (en) * | 2008-03-10 | 2009-09-16 | mivenion GmbH | Polyether polyol dendron conjugates with effector molecules for biological targeting |
US8389768B2 (en) | 2008-05-19 | 2013-03-05 | The University Of North Carolina At Chapel Hill | Methods and compositions comprising novel cationic lipids |
-
2011
- 2011-01-31 ES ES11701951T patent/ES2730744T3/es active Active
- 2011-01-31 CA CA2788736A patent/CA2788736C/en active Active
- 2011-01-31 AU AU2011212742A patent/AU2011212742B2/en active Active
- 2011-01-31 WO PCT/EP2011/000425 patent/WO2011095311A1/en active Application Filing
- 2011-01-31 NZ NZ601550A patent/NZ601550A/en unknown
- 2011-01-31 HU HUE11701951A patent/HUE045311T2/hu unknown
- 2011-01-31 JP JP2012551541A patent/JP5866301B2/ja active Active
- 2011-01-31 BR BR112012019520-4A patent/BR112012019520A2/pt not_active IP Right Cessation
- 2011-01-31 CN CN2011800083136A patent/CN102781478A/zh active Pending
- 2011-01-31 US US13/576,779 patent/US8877171B2/en active Active
- 2011-01-31 PL PL11701951T patent/PL2531221T3/pl unknown
- 2011-01-31 EP EP11701951.3A patent/EP2531221B1/en active Active
- 2011-01-31 DK DK11701951.3T patent/DK2531221T3/da active
-
2015
- 2015-10-09 JP JP2015200718A patent/JP2016026191A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2013518841A (ja) | 2013-05-23 |
CN102781478A (zh) | 2012-11-14 |
JP2016026191A (ja) | 2016-02-12 |
HUE045311T2 (hu) | 2019-12-30 |
WO2011095311A1 (en) | 2011-08-11 |
PL2531221T3 (pl) | 2020-05-18 |
US20130095035A1 (en) | 2013-04-18 |
CA2788736C (en) | 2020-03-31 |
ES2730744T3 (es) | 2019-11-12 |
EP2531221A1 (en) | 2012-12-12 |
JP5866301B2 (ja) | 2016-02-17 |
NZ601550A (en) | 2014-03-28 |
CA2788736A1 (en) | 2011-08-11 |
DK2531221T3 (da) | 2019-06-17 |
US8877171B2 (en) | 2014-11-04 |
AU2011212742A1 (en) | 2012-08-30 |
EP2531221B1 (en) | 2019-03-13 |
AU2011212742B2 (en) | 2014-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012019520A2 (pt) | macromoleculas multivalentes polianionicas para alvejamento intracelular da sintese de proteina e proliferacao | |
AR114031A2 (es) | Moléculas de unión a 4-1bb | |
CU20200089A7 (es) | Moléculas de unión contra bcma | |
BR112012025568A2 (pt) | proteínas de ligação ao tnf-<244>. | |
UY31533A1 (es) | Moleculas de enlace al receptor humano ox40 | |
BR112014000324A8 (pt) | reagentes reticulantes, macromoléculas, conjugados terapêuticos e métodos sintéticos dos mesmos | |
BR112015009931A2 (pt) | gene, proteína, molécula de ácido nucleico, vetor, célula hospedeira, métodos para a preparação in vitro de um gene mutante e para gerar uma planta, planta mutante, produto, semente de planta mutante, anticorpo, uso de um anticorpo, sonda genética, par de oligonucleotídeos iniciadores, e, uso de sonda genética | |
BR112013020338A2 (pt) | proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira | |
MX2010005830A (es) | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. | |
AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
BR112013021134A8 (pt) | Anticorpo isolado que se liga especificamente a ptk7 humano, seu uso, composição farmacêutica que o compreende, e ácido nucleico | |
BRPI0922106A2 (pt) | anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição | |
EA201690492A1 (ru) | Проникающие в клетку конъюгаты и способы их применения | |
EA201390642A1 (ru) | Цитотоксические агенты, содержащие новые производные анзамитоцина | |
BRPI1006368A2 (pt) | proteína de fusão. molécula de ácido nucleico, vetor, célula modificada geneticamente, método para produção da proteína de fusão, usos da proteína de fusão, composição, método para preparação de uma composição, kits, método e uso da proteína de fusão | |
BR112012020693A8 (pt) | Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende | |
AR079551A1 (es) | Anticuerpos anti-her3 y usos de los mismos | |
WO2012075040A3 (en) | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES | |
BR112013003825A2 (pt) | conjugados, partículas, composições e métodos relacionados | |
CL2011002756A1 (es) | Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad. | |
MX341416B (es) | Profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos. | |
MX2009012358A (es) | Agentes de formacion de imagenes opticas. | |
CU20130047A7 (es) | Conjugado de naloxol-peg cristalino | |
MX2014008373A (es) | Conjugados antagonistas de integrina para suministro dirigido a celulas que expresan alfa-v-beta-3. | |
AR080680A1 (es) | Proteinas de union a basigina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |